BioCentury
ARTICLE | Politics, Policy & Law

Biopharma industry, academics push back against demands for price controls on COVID-19 countermeasures

February 21, 2020 12:09 AM UTC
Updated on Mar 26, 2020 at 1:49 AM UTC

The biopharma industry and academics who are developing vaccines and therapies to prevent and treat COVID-19 pushed back Thursday against calls from members of Congress for price controls on medical countermeasures.

In a letter to President Donald Trump, 46 House Democrats asked him to “ensure that any vaccine or treatment developed with U.S. taxpayer dollars be accessible, available, and affordable.” They added that this goal “cannot be met if pharmaceutical corporations are given authority to set prices and determine distribution, putting profit-making interests ahead of public health priorities.”...